Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Clinical research trials and Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract. Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract clinical trial. Subjects frequently obtain the most expert healthcare possible for their Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "V" Clinical Trials Conditions > Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract



Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

For Condition: Gastrointestinal Cancer
Status: Recruiting
Sponsor(s): University of Texas , National Cancer Institute (NCI)
Synopsis: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomizedphase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the gastrointestinal tract.
Details: OBJECTIVES: - Determine whether immunization with carcinoembryonic antigen (CEA) peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant or dissolved in sargramostim (GM-CSF) can generate CAP 1-6D-specific T cells in patients with CEA-producing adenocarcinomas of gastrointestinal tract origin. - Determine whether vaccination with CAP 1-6D can generate cytotoxic T cells against CEA-expressing tumors in these patients. - Determine whether this vaccine can produce antitumor responses in these patients. - Determine the frequency and severity of toxic effects associated with this vaccine in these patients. OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1. - Arm II: Patients receive CAP 1-6D dissolved in sargramostim (GM-CSF) intradermally on day 1. Treatment repeats in both arms every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 weeks and then as necessary. PROJECTED ACCRUAL: A total of 10-36 patients (5-18 per arm) will be accrued for this study within 36 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed stage II, III, or IV adenocarcinoma of the gastrointestinal tract originating in 1 of the following: - Esophagus - Stomach - Pancreas - Small intestine - Colon or rectum - Gall bladder - Extrahepatic bile ducts - Ampulla of Vater - Completed standard therapy and at risk of recurrent disease OR has relatively stable metastatic disease and a life expectancy of at least 6 months - Carcinoembryonic antigen (CEA)-producing tumor as evidenced by detectable blood levels of CEA or positive for CEA on immunohistochemical staining - HLA-A2+ PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-1 Life expectancy: - See Disease Characteristics Hematopoietic: - WBC at least 4,000/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 8 g/dL Hepatic: - SGOT or SGPT no greater than 3 times upper limit of normal - Hepatitis B and C negative Renal: - Creatinine no greater than 2.0 mg/dL Other: - No other prior malignancy unless currently disease free and off all therapy for that malignancy - Early skin cancer allowed - No AIDS - HIV negative - Not pregnant or nursing - Fertile patients must use effective contraception during and for 30 days after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy Chemotherapy: - At least 4 weeks since prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - At least 4 weeks since prior surgery Other: - No other concurrent therapy for malignancy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
RobertWhitehead,  Study Chair,  University of Texas

University of Texas Medical Branch *Recruiting*
Galveston,  Texas,  77555-0565
United States
Recruiting Robert  Whitehead 409-772-1164


Additional Information:
Study ID Numbers:  CDR0000068497;  NCI-931,UTMB-NCI-931
Study Start Date: 
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012246

Other Gastrointestinal Cancer Studies:
1. Genetic Study of Patients and Families With a History of Colorectal Cancer

2. Chemotherapy in Treating Patients With Solid Tumors

3. Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

4. High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

5. Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Related Studies:

Other Gastrointestinal Cancer Clinical Trials
Other Texas Clinical Trials
Other Galveston Clinical Trials

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
Modify your Search

  Other Gastrointestinal Cancer Clinical Trials
  Other Texas Clinical Trials
  Other Galveston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103